Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Avatar

Discrepancy Between Real World vs. Clinical Trial Data in Relapsed/Refractory Multiple Myeloma Treatment

By Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019) FEATURING Meletios Dimopoulos
October 17, 2019
0 Comments
Login to view comments. Click here to Login

Related Content

AUTOPLAY
Total Health Conferencing

2021 ASCO Virtual Direct™ Highlights St. Louis

Sat, Jun 26, 2021
See 3 others
05:09
Association of Community Cancer Centers (ACCC)

72 y/o Woman With IgG Lambda High-Risk Multiple Myeloma (del17p): Disease …

Feat. K. Maples
30:19
SOHO Italy 1st School of Multiple Myeloma

Present & Near Future of R/R MM: Post-Bortezomib, Post-Lenalidomide, Selin…

Feat. C. Cerchione
14:15
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

MRD in Multiple Myeloma Isn't Ready for Prime Time: More Patients Can Achi…

Feat. T. Martin
18:43
7th Eurasian Hematology Oncology Summit

2020 Updates on CAR-T in R/R MM: What Is the Incidence of AEs With bb2121?…

Feat. E. Terpos
23:44
UAB Hematology Review 2021

Therapeutic Options for R/R MM: Single Agent vs. Doublets vs. Triplets, Su…

Feat. K. Godby
26:18
Morie Gertz

Treatment of Relapsed Myeloma: Overview of Approved Drugs & Optimal Sequen…

12:53
2nd SOHO Italian Conference

Genetic Profiling in MM: Can Genomics Help With High-Risk Disease? How Can…

Feat. N. Bolli
05:11
UChicago 6th Annual Updates from ASH 2020: Practice Changing Abstracts

ASH Updates on R/R MM: How to Choose Amongst Available Regimens at 1st Rel…

Feat. B. Derman
08:15
2018 Pan Pacific Lymphoma Conference

Evolution of Myeloma Induction Regimens

Feat. S. Holstein
25:51
KU ASH 2018 Review: Current Updates in Hematologic Diseases

MM - Overview of Trials Presented at ASH 2018

Feat. A. Abdallah
09:00
5th Annual West Oncology Conference at Graceland: Advances in the Business of Science of Oncology

Treatment Options in R/R Multiple Myeloma: Tips for Selecting Among the My…

Feat. J. Berdeja
09:50
Nina Shah

Maximizing the Initial Gains in Myeloma Therapy: Consolidation and Mainten…

12:03
Andrew Cowan

BCMA CAR-T + Gamma Secretase Inhibitor Appear to Be Well Tolerated in R/R …

06:12
Indy Hematology Review

Targeting Mutations in Myeloma with Venetoclax and Development of the Fi...

Feat. K. Anderson
19:41
Peter Voorhees

Approach to the Patient with Refractory & Multiple Relapsed Multiple Myelo…

15:22
SOHO Italy 1st School of Multiple Myeloma

Dissecting Daratumumab Mechanisms of Resistance in MM: Identification of N…

Feat. M. Claudio Da Via
10:30
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)

Next Questions in Myeloma: Biology, Smoldering Myeloma, High-risk, MRD, an…

Feat. S. Jagannath
15:02
Krina Patel

Clinical Trials in Myeloma in 2018

15:47
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)

Myeloma State of the Art Update: Bone Disease, MRD Assessment, How to Mana…

Feat. S. Lonial
15:31
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

ASH 2019 Relapsed Myeloma Highlights: Can Biomarkers Predict Response to...

Feat. A. Rosko